Mescaline

Mescaline (3,4,5-trimethoxyphenethylamine) is a naturally occurring phenethylamine alkaloid and classical serotonergic psychedelic first isolated from the peyote cactus (Lophophora williamsii) by Arthur Heffter in 1897 and first synthesized by Ernst Spath in 1919. It holds the distinction of being the first psychedelic compound to be extracted, chemically characterized, and synthesized from a botanical source, and the parent scaffold for the substituted phenethylamine family that produced the 2C series, the DOx amphetamines, and the escaline analogs. The primary mechanism of psychedelic action is partial agonism at the serotonin 5-hydroxytryptamine type 2A (5-HT2A) receptor, with functional EC50 greater than 10,000 nM and intrinsic activity of approximately 56 percent of the serotonin maximum in heterologous expression systems. The compound also displays measurable affinity at 5-HT2C (Ki approximately 9,900 nM), 5-HT2B (Ki approximately 800 nM), 5-HT1A (Ki approximately 6,700 nM), alpha-2A adrenergic (Ki approximately 2,000 nM), and trace amine-associated receptor 1 (TAAR1, Ki approximately 3,300 to 11,000 nM) targets, but co-administration of the selective 5-HT2A antagonist ketanserin at 40 mg strongly reduces all acute subjective and autonomic effects, confirming 5-HT2A receptor activation as the dominant mediator of the psychedelic response.

Pharmacokinetics in humans are characterized by rapid oral absorption (time to peak plasma concentration approximately 2.0 hours), dose-proportional exposure from 100 to 800 mg, a plasma elimination half-life of approximately 3.5 hours, and oral bioavailability of at least 53 percent. First-pass hepatic metabolism accounts for approximately 50 percent of an oral dose, producing the primary metabolite 3,4,5-trimethoxyphenylacetic acid (TMPAA) through oxidative deamination. Renal excretion is the principal elimination pathway, with approximately 53 percent of the dose recovered as unchanged mescaline and 31 percent as TMPAA in urine within 24 to 30 hours. The apparent volume of distribution is approximately 217 liters, indicating extensive tissue distribution. Renal clearance substantially exceeds glomerular filtration rate, indicating active tubular secretion.

Two modern phase 1 clinical trials at University Hospital Basel have established the dose-response pharmacology of mescaline hydrochloride at 100 to 800 mg in healthy participants under double-blind, placebo-controlled conditions. Subjective psychedelic effects are dose-dependent with no ceiling effect observed within the tested range; 500 mg mescaline produces effects approximately equivalent to 100 micrograms of lysergic acid diethylamide or 20 mg of psilocybin. Duration of subjective effects increases from approximately 6.4 hours at 100 mg to approximately 14 hours at 800 mg, a dose-dependent prolongation attributable to the pharmacokinetic-pharmacodynamic relationship rather than to metabolite accumulation. The principal acute adverse effects are dose-dependent nausea and emesis (7 of 16 subjects at 800 mg), fatigue, headache, sympathomimetic cardiovascular activation (elevated systolic and diastolic blood pressure, heart rate, and body temperature), and mydriasis. Anxiety emerged as a significant subjective adverse effect only at the 800 mg dose.

Archaeological and ethnobotanical evidence documents ceremonial use of mescaline-containing cacti spanning more than 6,000 years in Mesoamerican and North American indigenous traditions. Epidemiological studies of Native American Church peyote users have not identified significant deficits on standardized mental health assessments, nor evidence of hallucinogen persisting perception disorder, dependence, or addiction in ceremonial contexts. The compound is classified as Schedule I in the United States, with an exemption for sacramental use by enrolled members of the Native American Church under the American Indian Religious Freedom Act Amendments of 1994. No controlled clinical trials for psychiatric indications have been completed; the current evidence base for therapeutic application in depression, anxiety, and substance use disorders is limited to ethnopharmacological observation, case series, and the historical literature from the mid-twentieth century. This monograph reviews the chemistry, synthesis, and structure-activity relationships of mescaline; the receptor pharmacology in molecular detail; the comprehensive human pharmacokinetic record; the preclinical and clinical evidence base; sourcing, reconstitution, and handling considerations for laboratory work; stack-interaction implications; adverse-event and safety signal; and a comparative assessment of five serotonergic psychedelic compounds against mescaline on five competency standards.